Actively Recruiting
The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea
Led by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Updated on 2026-03-24
186
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study
CONDITIONS
Official Title
The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 70 years who voluntarily agree to participate and sign informed consent
- Diagnosed with erythematous telangiectatic rosacea according to Chinese Guidelines
- Have an Investigator's Global Assessment (IGA) score of 2 (mild) or 3 (moderate) at screening and baseline
- Agree not to use any other rosacea treatment drugs during the study
- Willing to minimize external triggers of rosacea like spicy food, alcohol, and sun exposure
- Agree to avoid conception and use effective contraceptive measures during the study and for 3 months after
You will not qualify if you...
- Diagnosed with papulopustular, hypertrophic, ocular, or other special types of rosacea
- Have active facial skin diseases during screening or baseline that could interfere with study assessments
- Have underlying serious diseases or had major surgeries within 6 months before screening
- Have abnormal lab results with clinical significance at screening or baseline
- Received LED light therapy on face within past 2 weeks
- Had facial laser, IPL, microneedle radiofrequency, chemical peels, or similar treatments within past 6 weeks
- Have facial infections currently requiring systemic treatment
- Have not completed required washout periods for certain topical or systemic treatments before baseline
- Use drugs known to cause acne-like rashes
- Used exfoliating or astringent products within past 2 days or plan to use during study
- History of alcohol abuse in past 2 years or drug abuse in past 5 years
- Infected with HIV, active hepatitis B or C, or active syphilis infection
- Plan to become pregnant or breastfeed during the study
- Sensitive to light or using photosensitive drugs
- Allergic to Hirudoid, tofacitinib, doxycycline, hydroxychloroquine, or their ingredients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Yiwu, Zhejiang, China, 322000
Actively Recruiting
Research Team
L
Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here